Arcadia Biosciences (RKDA) Announces Strong Third-Quarter Financial Results and Business Highlights

- Advertisement -

DAVIS, Calif., Nov. 15, 2021 /PRNewswire/ — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the third quarter of 2021.

Arcadia Biosciences Logo (PRNewsfoto/Arcadia Biosciences, Inc.)

“Our third quarter was a continuation of the exciting momentum Arcadia has generated since the beginning of the year, as we again produced strong financial results that further validate our successful transformation into a consumer products company,” said Matt Plavan, CEO of Arcadia. “The quarter also was marked by a heightened intensity of focus, building on the significant progress we have made in capacity-building, integration and alignment of resources. 

“To help ensure the positive trajectory continues, we’ve been persistent – with our expanded bench of CPG talent in place – in honing our focus, further refining our go-to-market strategies for 2022 and identifying ways to accelerate our path forward,” he added. 

Q3 and Recent Operating and Business Highlights

  • Arcadia Expands Distribution of Body Care Products. The company significantly expanded its distribution of body care products compared to the prior year third quarter, which bodes well for continued retail growth. We estimate that distribution for our three body care brands expanded by nearly 80% compared to the prior year, primarily driven by the launch of ProVaultTM in Q1 2021.

     

    In addition, a new ProVault site – getprovault.com – went live in October, supported by a digital marketing and advertising campaign. Two remaining product sites are expected to launch by the end of the year, including the rebranded e-commerce sites for Saavy Naturals® (saavynaturals.com) and SoulSpringTM (mysoulspring.com).

     
  • Arcadia Advances Plans for GoodWheatTM Launch. A full-scale launch of five pasta SKUs supported by a comprehensive, consumer-focused marketing campaign will launch in Q1 of 2022, rather than a soft launch of one SKU in December 2021. As part of this effort, the company has made meaningful progress preparing GoodWheat pasta products for entrée into the consumer retail channel, including developing and testing consumer-preferred packaging.

     
  • Arcadia Successfully Harvests Hawaiian Hemp Biomass. Arcadia successfully harvested more than 20,000 lbs. of Hawaiian hemp biomass. The company is currently processing the biomass and expects the resulting output to be the largest supply of Hawaiian CBD on the market today. An analysis of options to optimally monetize this asset is currently underway in cooperation with our partner in Archipelago Ventures.

Arcadia Biosciences, Inc.

Financial Snapshot

(Unaudited)

($ in thousands)



Three Months Ended September 30,


Nine Months Ended September 30,


2021

2020

Favorable/

(Unfavorable)


 

2021

2020

Favorable/

(Unfavorable)




$

%




$

%

Total revenues

2,376

314

2,062

657%


4,609

904

3,705

410%

Total operating expenses

11,089

7,895

(3,194)

(40%)


26,331

21,151

(5,180)

(24%)

Loss from operations

(8,713)

(7,581)

(1,132)

(15%)


(21,722)

(20,247)

(1,475)

(7%)

Net loss attributable to

common stockholders

(2,175)

(6,391)

4,216

66%


(5,378)

(13,553)

8,175

60%

Revenues

In the third quarter of 2021, revenues were $2.4 million, compared to revenues of $314,000 in the third quarter of 2020, and for the nine months ended September 30, 2021 revenues were $4.6 million, compared to $904,000 in the nine months ended September 30, 2020. The $2.1 million quarter-over-quarter increase was primarily driven by the sales related to the newly acquired portfolio of wellness brands. The $3.7 million year-over-year increase was driven by the aforementioned, in addition to GoodHemp seed, GoodWheat grain and increased GLA oil sales during the first nine months of 2021.

Operating Expenses

In the third quarter of 2021, total operating expenses were $11.1 million compared to $7.9 million in the third quarter of 2020, and in the nine months ended September 30, 2021, total operating expenses were $26.3 million compared to $21.2 million in the nine months ended September 30, 2020.

Cost of product revenues in the third quarter of 2021 were $670,000 higher than in the third quarter of 2020. Third quarter 2021 included costs associated with the newly acquired portfolio of wellness brands, along with $449,000 of write-downs of hemp seed inventory to fair value and the destruction of hemp crops, while the three months ended September 30, 2020 included $1.5 million in write-downs. Cost of product revenues for the nine months ended September 30, 2021 were $1.5 million higher than in the nine months ended September 30, 2020, primarily driven by sales of the newly acquired product lines, partially offset by lower write-downs during 2021.

Research and development (R&D) expense decreased by $724,000 and $2.7 million for the third quarter and nine months ended September 30, 2021 and 2020, respectively, primarily due to lower employee expenses as we right-sized our research teams, along with the absence of Verdeca related activity in 2021. Partially offsetting the favorability for the quarter and year to date is a $333,000 expense included in 2021 for the release of product from inventory that was not commercialized by Arcadia.

A write-down of fixed assets in the amount of $1.1 million was recognized in the third quarter of 2021 as a result of the assessed impairment of Archipelago fixed assets due to regulatory challenges and unfavorable market conditions for hemp. The write-down totaled $1.3 million third quarter 2021 year to date, while there was no such write-down during 2020.

General and administrative (SG&A) costs for the quarter and nine months ended September 30, 2021 were $2.0 million and $5.1 million higher than in the quarter and nine months ended September 30, 2020, respectively, resulting in part from the acquisitions, including investment banker success fees, legal diligence and transaction fees, as well as additional salaries and benefits with the increased headcount. Marketing, advertising and consulting activities increased in 2021 as well.

Net Loss Attributable to Common Stockholders

Net loss attributable to common stockholders for the third quarter of 2021 was $2.2 million, or $0.10 per share, a $4.2 million decrease from the $6.4 million, or $0.60 per share, net loss for the third quarter of 2020. The third quarter of 2021 included $1.1 million of other income for the gain on extinguishment of the Paycheck Protection Program loan and $4.8 million of non-cash income recognized as a result of the decrease in the fair value of common stock warrant liabilities. The third quarter of 2020 included $1.1 million of non-cash income for the decrease in the fair value of common stock warrant liabilities.

Net loss attributable to common stockholders for the first nine months of 2021 was $5.4 million, or $0.26 per share, a $8.2 million decrease from the $13.6 million, or $1.42 per share, net loss for the first nine months of 2020. A realized gain on the sale of Bioceres shares in the amount of $10.2 million was recognized in the first nine months of 2021. Non-cash income of $4.6 million was recorded in the first nine months of 2021 for the decrease in the fair value of common stock warrant liabilities, while $6.2 million of non-cash income was recorded during the first nine months of 2020 for the decrease in the fair value of common stock warrant liabilities.

Conference Call and Webcast

The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) today, November 15, to discuss third-quarter financial results and key strategic achievements.

Interested participants can join the conference call using the following numbers:

U.S. Toll-Free Dial-In:        

+1-844-243-4690

International Dial-In:        

+1-225-283-0138

Passcode:                       

9543419

A live webcast of the conference call will be available on the “Investors” section of the Arcadia website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company’s investor website.

About Arcadia Biosciences, Inc.

With origins as a trailblazing developer of science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, Arcadia Biosciences (Nasdaq: RKDA) is now a producer of innovative, plant-based health and wellness products, which include GoodWheat™, Soul Spring™, ProVault™, Saavy Naturals® and Zola® coconut water. The company’s growing number of innovative offerings are designed to enhance quality and health benefits in an array of consumer product categories. For more information, visit www.arcadiabio.com.

Safe Harbor Statement

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to projected revenue growth as a result of the asset acquisition. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the price and demand for the company’s products are lower than expected; the company’s and its partners’ and affiliates’ ability to develop and sell commercial products incorporating its traits, and complete the regulatory review process for such products; the company’s compliance with laws and regulations that impact the company’s business, including the sale of products containing CBD, and changes to such laws and regulations; the growth of the global wheat and hemp markets; the successful integration of the acquired brands and assets into Arcadia’s business; the potential impact of COVID-19 on the company’s business; and the company’s future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company’s financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled “Risk Factors” and additional information set forth in its Form 10-K for the year ended December 31, 2020, and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update these forward-looking statements.

 

Arcadia Biosciences, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)










September 30,

2021



December 31,

2020


Assets







Current assets:







Cash and cash equivalents


$

35,526



$

14,042


Short-term investments






11,625


Accounts receivable



1,453




1,406


Inventories, net — current



5,447




3,812


Prepaid expenses and other current assets



1,408




811


Total current assets



43,834




31,696


Restricted cash






2,001


Property and equipment, net



2,634




3,539


Right of use asset



3,486




5,826


Inventories, net — noncurrent



3,539




3,485


Goodwill



1,648




408


Intangible assets, net



3,905




370


Other noncurrent assets



182




23


Total assets


$

59,228



$

47,348


Liabilities and stockholders’ equity







Current liabilities:







Accounts payable and accrued expenses


$

5,004



$

4,105


Amounts due to related parties



51




80


Debt — current



36




1,141


Unearned revenue — current






8


Operating lease liability — current



1,134




717


Other current liabilities



264




263


Total current liabilities



6,489




6,314


Debt — noncurrent



78




2,105


Operating lease liability — noncurrent



2,562




5,389


Common stock warrant liabilities



7,736




2,708


Other noncurrent liabilities



2,140




2,280


Total liabilities



19,005




18,796


Commitments and contingencies







Stockholders’ equity:







Common stock, $0.001 par value—150,000,000 shares authorized as of

September 30, 2021 and December 31, 2020; 22,184,235 and 13,450,861

shares issued and outstanding as of September 30, 2021 and December

31, 2020, respectively



63




54


Additional paid-in capital



257,009




239,496


Accumulated other comprehensive income



(24)





Accumulated deficit



(217,203)




(211,825)


Total Arcadia Biosciences stockholders’ equity



39,845




27,725


Non-controlling interest



378




827


Total stockholders’ equity



40,223




28,552


Total liabilities and stockholders’ equity


$

59,228



$

47,348


 

Arcadia Biosciences, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share data)




Three Months Ended

September 30,



Nine Months Ended

September 30,





2021




2020




2021




2020


Revenues:













Product


$

2,324



$

245



$

4,506



$

630


License



17




10




17




110


Royalty



35




16




86




58


Contract research and government grants






43







106


Total revenues



2,376




314




4,609




904


Operating expenses:













Cost of product revenues



2,511




1,841




4,954




3,463


Research and development



1,038




1,762




3,328




5,999


Impairment of intangible assets



120







120





Change in fair value of contingent consideration









(140)





Write-down of fixed assets



1,108







1,319





Selling, general and administrative



6,312




4,292




16,750




11,689


Total operating expenses



11,089




7,895




26,331




21,151


Loss from operations



(8,713)




(7,581)




(21,722)




(20,247)


Interest expense



(15)




(23)




(23)




(32)


Other (expense) income, net



(7)







10,214




83


Change in fair value of common stock warrant liabilities



4,777




1,130




4,601




6,212


Loss on extinguishment of warrant liability






(682)







(635)


Gain on extinguishment of PPP loan



1,123







1,123





Issuance and offering costs









(769)





Net loss before income taxes



(2,835)




(7,156)




(6,576)




(14,619)


Income tax provision



(1)




(9)




(1)




(15)


Net loss



(2,836)




(7,165)




(6,577)




(14,634)


Net loss attributable to non-controlling interest



(661)




(774)




(1,199)




(1,081)


Net loss attributable to common stockholders


$

(2,175)



$

(6,391)



$

(5,378)



$

(13,553)


Net loss per share attributable to common stockholders:













Basic and diluted


$

(0.10)



$

(0.60)



$

(0.26)



$

(1.42)


Weighted-average number of shares used in per share

calculations:













Basic and diluted



22,177,423




10,719,618




20,976,105




9,570,259


Other comprehensive loss, net of tax













Unrealized losses on investment securities












(1)


Foreign currency translation adjustment



(12)







(24)





Other comprehensive loss



(12)







(24)




(1)


Comprehensive loss attributable to common stockholders


$

(2,187)



$

(6,391)



$

(5,402)



$

(13,554)


 

Arcadia Biosciences, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)




Nine Months Ended September 30,





2021




2020


CASH FLOWS FROM OPERATING ACTIVITIES:







Net loss


$

(6,577)



$

(14,634)


Adjustments to reconcile net loss to cash used in operating activities:







Change in fair value of common stock warrant liabilities



(4,601)




(6,212)


Loss (gain) on extinguishment of warrant liability






635


Change in fair value of contingent consideration



(140)





Issuance and offering costs



769





Depreciation



737




395


Amortization of intangible assets



99





Lease amortization



914




745


Impairment of intangible assets



120





Loss (gain) on disposal of fixed assets



17




(8)


Net amortization of investment premium






(44)


Stock-based compensation



1,035




1,844


Realized gain on corporate securities



(10,222)





Write-down of fixed assets



1,319





Write-down of inventory and prepaid production costs



1,802




3,063


Gain on extinguishment of PPP loan



(1,123)





Changes in operating assets and liabilities:







Accounts receivable



(47)




229


Inventories



(2,651)




(9,609)


Prepaid expenses and other current assets



(452)




(1,157)


Other noncurrent assets



(159)




(15)


Accounts payable and accrued expenses



972




2,026


Amounts due to related parties



(29)




(11)


Unearned revenue



(8)




(42)


Other current liabilities



1




(43)


Operating lease payments



(984)




(629)


Net cash used in operating activities



(19,208)




(23,467)


CASH FLOWS FROM INVESTING ACTIVITIES:







Proceeds from sale of property and equipment



2




8


Purchases of property and equipment



(919)




(2,038)


Acquisitions, net of cash acquired



(4,250)




(500)


Purchases of investments






(1,292)


Proceeds from sales and maturities of investments



21,845




18,250


Net cash provided by investing activities



16,678




14,428


CASH FLOWS FROM FINANCING ACTIVITIES:







Proceeds from issuance of common stock and warrants from January 2021

PIPE securities purchase agreement



25,147





Payments of offering costs relating to January 2021 PIPE securities

purchase agreement



(1,912)





Proceeds from the exercise of warrants



22




9,372


Proceeds from borrowings






3,108


Payment of transaction costs relating to extinguishment of warrant liability






(863)


Principal payments on debt



(2,032)




(26)


Proceeds from ESPP purchases



39




51


Capital contributions received from non-controlling interest



750




1,182


Net cash provided by financing activities



22,014




12,824


Effects of foreign currency translation on cash and cash equivalents



(1)





Net increase in cash, cash equivalents and restricted cash



19,483




3,785


Cash, cash equivalents and restricted cash — beginning of period



16,043




8,417


Cash, cash equivalents and restricted cash — end of period


$

35,526



$

12,202


SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:







Cash paid for income taxes


$

1



$

1


Cash paid for interest


$

25



$

7


NONCASH INVESTING AND FINANCING ACTIVITIES:







Fixed assets acquired with notes payable


$



$

37


Common stock warrants issued to placement agent and included in offering

costs related to May 2020 Warrant Transaction


$



$

215


Common stock warrants issued to placement agent and included in offering

costs related to July 2020 Warrant Transaction


$



$

101


Shares of common stock issued at closing of Arcadia Wellness transaction


$

2,053



$


Common stock warrants issued to placement agent and included in offering

costs related to January 2021 PIPE securities purchase agreement


$

942



$


Right of use assets obtained in exchange for new operating lease liabilities


$

1,662



$

4,157


Purchases of fixed assets included in accounts payable and accrued

expenses


$



$


 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-announces-strong-third-quarter-financial-results-and-business-highlights-301424512.html

SOURCE Arcadia Biosciences, Inc.

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Agrigate Global takes no editorial responsibility for the same.